Allin IP DX LLC, a laboratory based in Sarasota, Florida, has agreed to pay $980,000 to settle allegations that it violated the Anti-Kickback Statute and the False Claims Act. The company was accused of making unlawful payments to independent marketers for referring Medicare beneficiaries' lab specimens.
According to the U.S. Attorney’s Office for the Middle District of Florida, these actions took place between January 2 and June 15, 2023. During this period, Allin allegedly paid marketers in exchange for referrals, which led to false claims being submitted to Medicare. The laboratory voluntarily disclosed its conduct and cooperated with federal investigators by providing detailed information about the alleged violations.
The Anti-Kickback Statute is designed to prevent financial incentives from influencing medical decisions under federally funded healthcare programs such as Medicare and Medicaid. It aims to ensure that providers act in the best interests of their patients rather than for personal financial gain.
“This settlement is a reflection of our commitment to protect our healthcare programs and deter those who violate federal laws at the expense of our taxpayers,” said U.S. Attorney Gregory W. Kehoe. “Laboratory testing is important to our beneficiaries, and we will hold providers accountable to safeguard our programs and ensure the provision of appropriate lab services to patients.”
“Medicare beneficiaries rely on the integrity of the Medicare program,” said Special Agent in Charge Isaac M. Bledsoe of the U.S. Department of Health and Human Services, Office of Inspector General (HHS-OIG). “Today’s resolution demonstrates our continued commitment to holding providers accountable and ensuring that medical decisions are driven by patient needs, not illegal incentives.”
The investigation was conducted by HHS-OIG and managed by Assistant United States Attorney Sean Keefe.
Officials noted that these claims are only allegations; there has been no determination of liability.
